https://www.licempre.com.br/anvisa-na-46a-reuniao-do-ich-avancos-em-produtos-farmaceuticos/
June 12, 2023
The Brazilian Health Regulatory Agency (Anvisa) will be present at the 46th meeting of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). The event took place in Vancouver, Canada, from June 9th to 14th.
With 17 representatives, designated by the Council’s guidelines and Ordinance 1,520/2019, which establishes the regulatory action model for the incorporation of topics transmitted by the ICH, Anvisa will participate in the meetings of the assembly, the management committee, and 14 working groups. Meetings take place simultaneously, seeking to discuss scientific and technical aspects of the development and registration of pharmaceutical products.
In addition, the Agency will send another three representatives to participate in specific working group meetings, which will take place in Berlin, Germany, from June 12th to 16th.
Parallel to the ICH meetings, the meeting of the International Pharmaceutical Regulators Program (IPRP) will be held, which exclusively brings together regulatory authorities. This meeting aims to promote cooperation and the exchange of information on matters of mutual interest.
Currently, Anvisa occupies the vice-presidency of the IPRP Management Committee and participates in 27 working groups related to the ICH, counting on the expertise of 50 specialists.
The ICH is an initiative involving regulatory authorities and the pharmaceutical industry, aimed at discussing and harmonizing scientific and technical aspects related to the development and registration of pharmaceutical products. In addition to Brazil, the regulatory authorities of the European Union, the United States, Japan, Canada, Switzerland, Mexico, Singapore, South Korea, China, Saudi Arabia, Chinese Taipei, and Turkey are also part of the program.
Your Trusted Partner for Agile Pharmaceutical Product Registration
When it comes to the registration of pharmaceutical products, it is essential to rely on a specialized company that has extensive knowledge of the regulations and the agility to face the challenges of the process. It is in this context that Licempre stands out as your trusted partner.
With years of experience in the regulatory sector, Licempre is renowned for its expertise in pharmaceutical product registration. Our team is composed of highly qualified professionals, experienced with the rules and guidelines of the competent authorities, such as the Brazilian Health Regulatory Agency (Anvisa). Click the link and learn how we can help: https://www.licempre.com.br/como-saber-se-um-produto-precisa-de-registro-na-anvisa/.
One of the main advantages of relying on Licempre is the agility we offer throughout the registration process. We understand the importance of being able to obtain approval from authorities quickly and efficiently so that your company can bring its products to market as quickly as possible.
Licempre has in-depth knowledge of the technical requirements, necessary documentation and steps to be followed during the registration process. This allows us to assist your company in preparing all the required documentation, ensuring that all requirements are met following current regulations.
In addition, our team is constantly updated on changes and updates to regulations, ensuring your product complies with the latest requirements. This avoids rework and potential delays during the registration process.
When choosing Licempre as a partner, you will have access to specialized technical support throughout the process. Our team will be available to answer questions, provide guidance and closely monitor the progress of the registration, ensuring that everything is forwarded smoothly and efficiently.
No matter the size of your company or the complexity of your product, Licempre is prepared to help you obtain the registration of pharmaceutical products in an agile and efficient way. Trust our experience and knowledge to ensure the success of your registration process.